Literature DB >> 34837075

MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.

Sanjeev Kumar Srivastava1,2, Mohammad Aslam Khan1,2, Shashi Anand1,2, Haseeb Zubair1,2, Sachin Kumar Deshmukh1,2, Girijesh Kumar Patel1,2, Seema Singh1,2,3, Joel Andrews4, Bin Wang5, James Elliot Carter1, Ajay Pratap Singh6,7,8.   

Abstract

BACKGROUND: Aberrant activation of androgen receptor signalling following castration therapy is a common clinical observation in prostate cancer (PCa). Earlier, we demonstrated the role of MYB overexpression in androgen-depletion resistance and PCa aggressiveness. Here, we investigated MYB-androgen receptor (AR) crosstalk and its functional significance.
METHODS: Interaction and co-localization of MYB and AR were examined by co-immunoprecipitation and immunofluorescence analyses, respectively. Protein levels were measured by immunoblot analysis and enzyme-linked immunosorbent assay. The role of MYB in ligand-independent AR transcriptional activity and combinatorial gene regulation was studied by promoter-reporter and chromatin immunoprecipitation assays. The functional significance of MYB in castration resistance was determined using an orthotopic mouse model.
RESULTS: MYB and AR interact and co-localize in the PCa cells. MYB-overexpressing PCa cells retain AR in the nucleus even when cultured under androgen-deprived conditions. AR transcriptional activity is also sustained in MYB-overexpressing cells in the absence of androgens. MYB binds and promotes AR occupancy to the KLK3 promoter. MYB-overexpressing PCa cells exhibit greater tumorigenicity when implanted orthotopically and quickly regain growth following castration leading to shorter mice survival, compared to those carrying low-MYB-expressing prostate tumours.
CONCLUSIONS: Our findings reveal a novel MYB-AR crosstalk in PCa and establish its role in castration resistance.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34837075      PMCID: PMC9023474          DOI: 10.1038/s41416-021-01641-1

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  52 in total

1.  Transcriptional activation by the v-myb oncogene and its cellular progenitor, c-myb.

Authors:  K Weston; J M Bishop
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

2.  Myb proteins regulate the expression of diverse target genes.

Authors:  Georgina Lang; Jonathan R White; Mary J G Argent-Katwala; Christopher G Allinson; Kathleen Weston
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

3.  MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin.

Authors:  Arun Bhardwaj; Sanjeev K Srivastava; Seema Singh; Nikhil Tyagi; Sumit Arora; James E Carter; Moh'd Khushman; Ajay P Singh
Journal:  J Biol Chem       Date:  2016-05-31       Impact factor: 5.157

4.  Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance.

Authors:  Sanjeev K Srivastava; Arun Bhardwaj; Seema Singh; Sumit Arora; Steven McClellan; William E Grizzle; Eddie Reed; Ajay P Singh
Journal:  Carcinogenesis       Date:  2012-03-19       Impact factor: 4.944

Review 5.  Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications.

Authors:  Chiara Pisano; Marcello Tucci; Rosario Francesco Di Stefano; Fabio Turco; Giorgio Vittorio Scagliotti; Massimo Di Maio; Consuelo Buttigliero
Journal:  Crit Rev Oncol Hematol       Date:  2020-11-27       Impact factor: 6.312

Review 6.  Prostate cancer: measuring PSA.

Authors:  C Pezaro; H H Woo; I D Davis
Journal:  Intern Med J       Date:  2014-05       Impact factor: 2.048

7.  c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression.

Authors:  M A Thompson; M A Rosenthal; S L Ellis; A J Friend; M I Zorbas; R H Whitehead; R G Ramsay
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

Review 8.  Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms.

Authors:  Fritz H Schröder
Journal:  Eur Urol       Date:  2008-01-28       Impact factor: 20.096

Review 9.  Androgen receptor: structure, role in prostate cancer and drug discovery.

Authors:  M H Eileen Tan; Jun Li; H Eric Xu; Karsten Melcher; Eu-leong Yong
Journal:  Acta Pharmacol Sin       Date:  2014-06-09       Impact factor: 6.150

10.  CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.

Authors:  Arun Bhardwaj; Sanjeev K Srivastava; Seema Singh; Sumit Arora; Nikhil Tyagi; Joel Andrews; Steven McClellan; James E Carter; Ajay P Singh
Journal:  Oncotarget       Date:  2014-11-30
View more
  2 in total

Review 1.  The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.

Authors:  Liuxun Li; Jiangli Xu
Journal:  Clin Transl Oncol       Date:  2022-10-06       Impact factor: 3.340

Review 2.  Second generation androgen receptor antagonists and challenges in prostate cancer treatment.

Authors:  Yanhua Chen; Qianqian Zhou; William Hankey; Xiaosheng Fang; Fuwen Yuan
Journal:  Cell Death Dis       Date:  2022-07-21       Impact factor: 9.685

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.